Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — PharmAust — Shareholder Meeting (October 2021)
27 slides from Neurizon Therapeutics's shareholder meeting presentation, October 2021
Slide 1: AGM Presentation October 2021
rsonal use only PharmAust Limited is a clinical-stage company developing therapeutics for the treatment of different types of cancers, viral and neurological diseases, as well as providing highly specialised medicinal and synthetic chemistry services on a contract basis to clients ASX: PAA ACN 094 0
Slide 2: Online Attendees – Text Question Process
ONLINE ATTENDEES – TEXT QUESTION PROCESS 123-456-789 When the question function is rsonal use only available, the messaging tab will appear at the top of the screen To submit a question, type your question in the “Ask a question” box and press the send arrow Your question will be sent immediately fo
Slide 3: Online Attendees – Audio Question Process
ONLINE ATTENDEES – AUDIO QUESTION PROCESS 123-456-789 When the audio questions line is available, a rsonal use only link will appear on the home tab titled Asking Audio Questions If you would like to ask an audio question, pause the meeting broadcast and click on the link You will be prompted to ent
Slide 4: Online Attendees – Voting
ONLINE ATTENDEES – VOTING 123-456-789 When open, the vote will be rsonal use only accessible by selecting the voting tab at the top of the screen To vote simply select the direction in which you would like to cast your vote. The selected option will change colour For Against Abstain There is no subm
Slide 5: Board and Management
rsonal use only Board and Management Dr Roger Aston – Executive Chairman Robert Bishop– Executive Director Sam Wright – Finance Director Dr Richard Mollard – Chief Scientific Officer Neville Bassett AM – Non-Executive Director Colin La Galia – Epichem CEO AGM Presentation October 2019 5
Slide 6: Proxy votes received
rsonal use only Proxy votes received AGM Presentation October 2021 6
Slide 7: Monepantel: Repurposing Monepantel
MONEPANTEL “REPURPOSING MONEPANTEL” rsonal use only • REGISTERED IN 38 COUNTRIES AS A VETERINARY ANTIPARASITIC • PHASE 3 IN CANINE CANCER START APR 2022 FOR REGISTRATION • RE-FORMULATED MONEPANTEL AS TABLET FOR CANINE AND HUMAN CANCER • DISCUSSIONS RECENTLY INITIATED WITH MAJOR PHARMACEUTICAL COMPAN
Slide 8: Monepantel Value Proposition
MONEPANTEL VALUE PROPOSITION rsonal use only SAFETY EFFICACY • Good safety profile no chemotherapy-like side effects • Extends survival x 4 cf untreated • No weight loss (at least stable disease induced) • No inappetence • Extends survival x 2 cf steroid standard of care • Good Quality of Life (at l
Slide 9: PharmAust: Canine Cancer Programme Update
PHARMAUST: CANINE CANCER PROGRAMME UPDATE: OPTIMAL DOSE rsonal use only • Fine tuning of Dose Optimization in Phase 2 Leading to Phase 3 • 100% of canines treated showing at least stable disease • Quadrupling mean-survival time over untreated • Doubling mean-survival time over prednisolone alone • D
Slide 10: Monepantel – Comparative Safety
MONEPANTEL – COMPARATIVE SAFETY PRODUCT PLACEMENT Chemotherapy (CHOP) Works Well But: Prednisolone: rsonal use only 1. Poor quality of Life Short Term Side Effects 2. Diarrhea Increased thirst and appetite 3. Vomiting Frequent urination 4. Bladder irritation Panting 5. Weight loss/ inappetence Letha
Slide 11: Monepantel Product Placement
MONEPANTEL PRODUCT PLACEMENT rsonal use only CHEMOTHERAPY PALLIATIVE CARE WHICH IS IN EFFECT PALLIATIVE CARE WITHOUT CHEMOTHERAPY 15% - 20% • 4-6 MONTHS • NO PAIN • GOOD QOL • NO TOX ISSUES • HOME MEDICATED EUTHANASIA 60%-80% DOGS WITH CANCER AGM Presentation October 2021 11
Slide 12: Monepantel How It Works
MONEPANTEL HOW IT WORKS rsonal use only PARALYSIS OF PARASITES mTOR ANTAGONIST –> TARGETING ACETYLCHOLINE RECEPTORS MONEPANTEL CURRENT SALES OF mTOR DRUGS: $2.5Bln mTOR plays a pivotal role governing cell growth and proliferation Therapeutic Targets: • Cancer (Vet and Human) • Motor Neurone Disease
Slide 13: Monepantel Tablet Stability and Impurity Analysis
MONEPANTEL TABLET STABILITY AND IMPURITY ANALYSIS rsonal use only MPL ACTIVE INGREDIENT SOURCED FROM SYNGENE INDIA (2 X 10 KG SCALE • At least 24 month shelf life TABLET SOURCING CAPABILITIES: • Impurity profile 15 x within limits CATALENT = PHASE 1 &2 SYNGENE = PHASE 3 AGM Presentation October 2021
Slide 14: PharmAust: Human Trial Program
MONEPANTEL PHARMAUST: HUMAN TRIAL PROGRAM rsonal use only • CLINICAL INTEREST TO FOCUS ON:GI, Principal Investigators in UK and Italy HUMAN GLIOBLASTOMA, CANCERS ESOPHAGEAL AND Identified for phase I/II trial PANCREATIC • HUMAN TRIAL IN FightMND Charity has awarded PharmAust $880,000 MOTOR MELBOURNE
Slide 15: Monepantel Strategy Moving Forward
MONEPANTEL STRATEGY MOVING FORWARD rsonal use only Strategy • With indicative commercially valuable phase 2 outcomes in canine cancer -> Complete phase 3 trial and License or sell Vet Cancer application • With good data in dogs showing significant periods of stable disease and progression-free survi
Slide 16: Clinical Timelines: Critical Timelines
CLINICAL TIMELINES MOVING FORWARD: CRITICAL TIMELINES rsonal use only AGM Presentation October 2021 16
Slide 17: Epichem
rsonal use only Epichem AGM Presentation October 2021 17
Slide 18: Epichem Pty Ltd: Medicinal & Synthetic Chemistry Expertise
EPICHEM PTY LTD: Medicinal & Synthetic Chemistry Expertise Worldwide customer base in Pharmaceutical, Biotech, Start Ups, Mining, Agriculture and Animal Health sectors State of the art, Purpose-Built facilities rsonal use only Medicinal Chemistry & Drug Discovery Proven Track Record of Success • Hit
Slide 19: OHD Waste Conversion & Re-purposing Technology
rsonal use only OHD Waste Conversion & Re-purposing Technology AGM Presentation October 2021 19
Slide 20: Policy Alignment & Government Incentives
rsonal use only Policy Alignment & Government Incentives AGM Presentation October 2021 20
Slide 21: OHD Benefits
rsonal use only OHD Benefits AGM Presentation October 2021 21
Slide 22: OHD ROI
rsonal use only OHD ROI AGM Presentation October 2021 22
Slide 23: OHD Highlights
rsonal use only OHD Highlights AGM Presentation October 2021 23
Slide 24: OHD Video
rsonal use only OHD Video • https://epichem.com.au/wp-content/uploads/2021/08/OHD-video-2021-08.mp4 AGM Presentation October 2021 24
Slide 25: Epichem 2021 Highlights
rsonal use only Epichem 2021 Highlights AGM Presentation October 2021 25
Slide 26: Q & A Session
Q & A SESSION www.pharmaust.com ASX: PAA rsonal use only @PharmAust FRA: ECQ ACN 094 006 023 AGM Presentation October 2021 26
Slide 27: Disclaimer
rsonal use only Disclaimer AGM Presentation October 2021 27